SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
It's been a rough few years for investors excited about new biopharmaceutical companies that use artificial intelligence (AI) to select new drug candidates. Less than three years after raising $510 ...
Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of ...
Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...
Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide ...
Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients Drug discovery research collaboration may initiate up to seven oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback